DESCRIPTION

*Current Problems in Cancer: Case Reports* is an international, peer-reviewed open access Journal which aims to fortify the field of oncology by publishing original case reports featuring prevention, diagnosis and treatment of cancer, supportive care, quality of life and rehabilitation. A companion title to *Current Problems in Cancer*, the Journal provides a global forum for clinicians and researchers to share their personal experiences through case reports, striving to inform clinical cancer research and care.

EDITORIAL BOARD

*Editor-in-Chief*

**Nam Quoc Bui**, Stanford University School of Medicine, Stanford, California, United States of America

Area of Expertise: Sarcoma, Developmental Therapeutics

*Associate Editors*

**Chris Chen**, Stanford University School of Medicine, Stanford, California, United States of America

Areas of expertise: Gastrointestinal cancer, early phase drug development

**Satya (Nanu) Das**, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States of America

Areas of Expertise: Gastrointestinal Oncology, Phase I, Drug Development

**Sunil A. Reddy**, Stanford University, Stanford, California, United States of America

Cutaneous Oncology, Evidence-Based Medicine, Lymphoma

**Kay T. Yeung**, University of California San Diego Moores Cancer Center, La Jolla, California, United States of America

Breast oncology

**Lisa C. Zaba**, Stanford University School of Medicine, Stanford, California, United States of America

Supportive Onco-dermatology, melanoma, merkel cell

*Advisory Reviewer Board*

**Moustafa Alkhalil**, Hamad Medical Corporation, Doha, Qatar

head and neck cancer

**Andrea Angelini**, University of Padova Department of Orthopedics and Orthopedic Oncology, Napoli, Italy

Musculoskeletal oncology and spine surgery

**Angel Artal**, Miguel Servet University Hospital Medical Oncology Service, Zaragoza, Spain

Thoracic malignancies

**Olutosin A. Awolude**, University of Ibadan College of Medicine, Ibadan, Nigeria

Preventive Gynaecology Oncology, Risk Reduction Interventions in genetic/familial women cancers, Prevention of HIV/HPV associated genital cancers
Warren Bacorro, University of Santo Tomas, Manila, Philippines
Brachytherapy, Cervical Cancer, Quality of Life, Head and Neck Cancer

Quim Megias Barrera, University Clinic Hospital of Santiago de Compostela, Santiago de Compostela, Spain
Head and neck surgery, Head and neck reconstructive surgery

Jelena Bila, University of Belgrade, Belgrade, Serbia
Hematology, Multiple myeloma, Amyloidosis, Macroglobulinemia Waldenstrom

Angelo Carella
Hematology and Bone Marrow Transplantation

Sakti Chakrabarti, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America
Medical oncology, GI oncology, Colorectal cancer, Gastric cancer, Esophageal cancer, circulating tumor DNA, Immunotherapy

Jayson L. Co, University of Santo Tomas Benavides Cancer Institute, Manila, Philippines
CNS/Brain Cancer, Pediatric Cancers, Imaging and Radiation Oncology

Faysal Dane, Acibadem Altunizade Hospital, Istanbul, Turkey
GI oncology, Breast cancer and GU oncology

Bharti Devnani, All India Institute of Medical Sciences, New Delhi, India
Oncology, Radiation Oncology, SBRT, Breast cancer, Head and neck cancers, CNS tumors, Cancer

Audrius Dulskas, Vilnius University Faculty of Medicine, Vilnius, Lithuania
Colorectal cancer, minimal invasive techniques, quality of life, functional changes

Eman Ahmed Elghoroury, National Research Centre, Cairo, Egypt
Molecular biology, mRNA, Gene polymorphism, Flow cytometr analysis, PCR, qPCR, clinical pathology, haematology and immunology

Luca Filippi, North Hospital, Latina, Italy
Nuclear Medicine, Nuclear Oncology, PET/CT, castration-resistant prostate cancer, hepatocellular carcinoma, radioembolization SIRT/TARE, targeted alpha therapy, Theranostics, neuroendocrine tumors

Cristian Fiori, University of Turin, Torino, Italy
Urology, prostate, kidney, adrenal, bladder cancers

Thomas Gardner, Indiana University Bloomington, Bloomington, Indiana, United States of America
Urologic Oncology, clinical trials, medical devices, molecular imaging

Sefonias Getachew, Addis Ababa University, Addis Ababa, Ethiopia
Epidemiology, health system, risk factors, interventional and observational studies

Michele Ghidini, IRCCS Maggiore Hospital, Ospedale Maggiore Policlinico, Milan, Italy
Gastrointestinal cancers, gastric cancer, liver cancer, colorectal cancer, pancreatic cancer, esophageal cancer

Alexandru Calin Grigorescu, Hospital of Nephrology Dr Carol Davila, Bucureşti, Romania
Medical Oncology, Palliative care

Sebastian Grosicki, Medical University of Silesia, Faculty of Health Sciences in Bytom, Department of Hematology and Cancer Prevention in Chorzow, Katowice, Poland
Hematology, internal medicine, therapy and diagnostics of multiple myeloma, acute leukemias, chronic leukemias

Mustafa Ozan Horsanali, Bakircay University Cigli Training and Research Hospital, İzmir, Turkey
Oncology, Endourology, Neuro-urology

Rashmi Maruti Hosalkar, MGM Dental College and Hospital, Mumbai, India
Oral Oncology, Oral Potentially Malignant Disorders, Odontogenic Cyst and Tumours, Vesiculobullous Lesions

Tasadoq Hussain, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America
Cleveland Clinic Foundation

Vamvakaris N. Ioannis, Sotiria General Hospital of Chest Diseases of Athens, Athens, Greece
NSCLC, MSC in oncology

Masaoki Ito, Nomura Hospital, Hiroshima, Japan
Cell culture, Extraction of protein, DNA, and RNA from cultured cells, surgical specimen, Immunohistochemistry, Western blotting, MTT assay, Cell invasion assay, Colony forming assay, Immunohistochemistry, Real-time PCR, PNA-LNA clamp PCR, Droplet digital PCR, Proteomics with 2-dimensional gel electrophoresis, Mass spectrometry, Confocal laser microscope, Laser micro dissection, Next-generation sequencer

Nusrat Jahan, Texas Tech University Health Sciences Center, Lubbock, Texas, United States of America
Breast oncology, genitourinary oncology, gastrointestinal oncology, immunotherapy, experimental cancer therapeutics.

Kaori Kameyama, Showa University Northern Yokohama Hospital, Yokohama, Japan
Thyroid and Parathyroid pathology

Govind Babu Kanakasetty, St John’s Medical College Hospital, Bangalore, India
Medical oncology, NSCLC and HNSCC
Thomas Karsten Kilvaer, UiT The Arctic University of Norway, Tromsø, Norway
Cancer biology, cancer biomarkers, artificial intelligence, sarcoma, NSCLC, radiotherapy

Jongphil Kim, H. Lee Moffitt Cancer Center and Research Institute Department of Biostatistics and Bioinformatics, Tampa, Florida, United States of America
Biostatistics, Design and Analysis of Phase I/II Clinical Trials, Multiple Comparisons, Time-To-Event Data Analysis, Concordance Analysis, BMT, Malignant Hematology, Imaging Data Analysis, Thoracic Oncology

Rohit Kumar, University of Louisville, Louisville, Kentucky, United States of America
Thoracic malignancy, Head and neck cancer, thrombosis

Roberto La Rocca, University of Naples Federico II Department of Neuroscience and Reproductive Sciences and Dentistry, Napoli, Italy
Urology, prostate cancer, kidney cancer, bladder cancer, penile cancer, urethral strictures.

Geun Dong Lee, Asan Medical Center Thoracic and Cardiovascular Surgery, Songpa-gu, South Korea
Lung and other thoracic tumors

Tiao Lin, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China
Osteoporosis, peri-prosthetic infection/bone loss, osteosarcoma, radiotherapy, chemotherapy

Luca Giovanni Locatello, University Hospital Careggi, Firenze, Italy
head and neck cancer, laryngeal cancer, salivary gland cancer, oral cavity cancer, otolaryngology-head and neck surgery, otorhinolaryngology

Celso Abdon Lopes de Mello, ACCamargo Cancer Center, Department of Medical Oncology, São Paulo, São Paulo, Brazil
Medical oncology, colorectal carcinoma, sarcoma, treatment, prognosis, circulating tumor cell

Vincent T. Ma, University of Michigan Medical School Division of Hematology/Oncology, Ann Arbor, Michigan, United States of America
Melanoma and other advanced cutaneous malignancies

Amita Maheshwari, Tata Memorial Centre, Mumbai, India
Gynecologic oncology, cervical cancer, ovarian cancer, uterine cancer

Sindhu Malapati, Ascension St John Hospital, Detroit, Michigan, United States of America
Breast Cancer

Saima Shakil Malik, University of Gujrat Department of Zoology, Gujrat, Pakistan
Genomics, Proteomics, Post translational modifications, Epigenetics, DNA repair mechanisms, Drugs associated cytotoxicity, Gene–environment interaction, Oncology, Pathology and Epidemiology

Ankit Mangia, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America
Soft-tissue Sarcoma, Melanoma, Bone Sarcoma

Antonino Maniaci, University of Catania Department of Surgical and Medical Sciences and Advanced Technologies "G.F. Ingrassia", Catania, Italy
Head and Neck cancer, oral cancer, laryngeal cancer

Yariswamy Manjunath, University of Missouri, Columbia, Missouri, United States of America
Translational Oncology, Biomarkers in Cancer, Circulating Tumor Cells, non-small cell lung cancer

Luca Marinelli, University of Rome La Sapienza, Roma, Italy
Radiation oncology

Saima Marjanović, University of Niš, Nis, Serbia
Immuo hematology, Non hodgkin lymphomas, chronic lymphocitic leukemia

Kriti Mittal, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
Medical oncology, genitourinary oncology, renal cell carcinoma, urothelial carcinoma, prostate cancer, testicular cancer, adrenal cancer

Nupur Mukherjee, National Institute for Research in Reproductive Health Department of Innate Immunity, Mumbai, India
Cancer Immunology, Molecular biology of Breast cancer, Translational Oncology, molecular therapeutics of cancer, Immunotherapy, transcription profiles of oncogenes, TSGs and pattern recognition receptors in cancer

Layth Mula-Hussain, University of Ottawa Divisions of Radiation Oncology, Ottawa, Ontario, Canada
Radiation oncology

Geeta S. Narayanan, Vydhevi Institute of Medical Sciences and Research Centre, Bangalore, India
Radiation oncology, Comparison of HPV genotype and response to chemo radiation in cervical cancer, Evaluation of telomerase as a tumor marker in head and neck cancer, Functional MRI imaging in cervical cancer brachytherapy, MRI adapted brachytherapy in cervical cancer, Evaluating the role of Neo adjuvant chemo therapy in various cancer sites

Ntokozo Ndlovu, University of Zimbabwe, Harare, Zimbabwe
Radiation/Clinical Oncology, Cancer, Cervical Cancer, Breast Cancer, HIV related Cancers, Prostate Cancer, Cancer Epidemiology

Hovav Nechushtan, Hadassah Medical Center, Jerusalem, Israel
Signal Transduction, Lung Cancer, Personalized Medicine (Oncology)
Rodrigo Otavio de Castro Araujo, National Institute for Cancer, Rio de Janeiro, Rio de Janeiro, Brazil
Surgical Oncology, Rectal Cancer, Translational research

Laura Palarea, A Lis Regional Health System of Liguria, Genova, Italy
Cancer prevention, molecular biology, drug repurposing, health technology assessment, pharmaco economics

Sunil Pasricha, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
Oncopathology

Iacopo Petrini, University of Pisa Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy
Thoracic oncology and genomic sequencing

Seth Politoano, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America
Medical Education, Health Equity, Case Reports

Juan Qian, Affiliated Hospital of Nantong University, , China
Hematology

Manglio Rizzo, Austral University Cancer Immunobiology Laboratory, Buenos Aires, Argentina
Lung cancer, immunotherapy, real world data, tumor microenvironment, extracellular matrix, hyaluronic acid, clinical trial

Yoelanda Rodriguez-Gil, Complutense University of Madrid, Madrid, Spain
Surgical pathology, Hepatology, Hepatocellular carcinoma and liver tumours, Colorectal cancer, Epstein Barr, virus related tumors, Tumours associated to transplant, Pancreas carcinoma, Neuroendocrine tumours,

Michael Kevin Rooney, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States of America
CNS malignancies, radiotherapy and the immune system, medical education, medical ethics, meta-research and bibliometrics

Muzaffer Sanci, Tepecik Training and Research Hospital Clinics, Konak, Turkey
Rare Genital Tumours

Vinit Shanbhag, University of Missouri, Columbia, Missouri, United States of America
Biochemistry, Biology of cancer, Drug discovery, and development, Molecular biology and signaling

Sunny RK Singh, Henry Ford Cancer Institute - Detroit, Detroit, Michigan, United States of America
Gastrointestinal Cancers, Genitourinary Cancers

Charalampos Siotos, Rush University Medical Center, Chicago, Illinois, United States of America
Breast cancer, mastectomy, breast reconstruction, oncoplastic surgery

Hooman Soleymani majd, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
laparoscopy, gynaecology oncology, ovarian cancer, ultra-radical surgery, debulking

Carmino Antonio de Souza, State University of Campinas, Campinas, Sao Paulo, Brazil
Onco hematology and bone marrow transplantation, CML and malignant lymphomas

Argiris Symeonidis, University of Patras, Patras, Greece
Gaucher disease, hematology, myelodysplastic syndromes, multiple myeloma, chronic myeloproliferative neoplasms, anemia, erythropoiesis, lymphoproliferative disorders, targeted treatments in hematology

Yuichi Tambo, Kanazawa University Hospital, Kanazawa, Japan
Lung Cancer, NSCLC, SCLC, Immuno Oncology, Targeted Therapy, Translational Research, Clinical Trial

Nikolaos Thomakos, National and Kapodistrian University of Athens, Athens, Greece
Perioperative care in Gyn/Oncology, Fertility sparing management in Gyn cancer

Anil Tombak, Mersin University, Mersin, Turkey
CLL, multiple myeloma, lymphoma

Mariza Vorster, University of Pretoria, Pretoria, South Africa
Nuclear medicine, theranostic, Ga-68-based PET, PET/CT, molecular imaging, targeted radionuclide therapy

Saman Warnakulasuriya, King's College London, London, United Kingdom
Oral Cancer, Screening, Risk factors, Epidemiology

Nathaniel R Wilson, The University of Texas Health Science Center at Houston, Houston, Texas, United States of America
Genitourinary oncology (bladder, kidney, prostate), immunotherapy for GU malignancies, immune-related adverse events from therapy

Che-Wei Wu, Kaohsiung Medical University College of Medicine, Taiwan
Head and Neck Cancer, Thyroid Cancer, Oral Cancer, Thyroid and Parathyroid Surgery, Intraoperative Neural Monitoring

Fevzi Yalniz, Legend Biotech, Piscataway, New Jersey, United States of America
Hematological malignancies including myeloid malignancies such as myelodysplastic syndromes and acute myeloid leukemias, lymphoid malignancies including chronic and acute leukemias as well as lymphomas, Adoptive cellular therapies including CAR-T, Stem cell transplantation

Jun (Vivien) Yin, Mayo Clinic, Department of Health Sciences Research, Jacksonville, Florida, United States of America
Bayesian adaptive clinical trial designs, predictive modeling, master protocols, precision oncology, surrogate endpoint, leukemia, hepatobiliary cancer
GUIDE FOR AUTHORS

INTRODUCTION

Case Report: Case reports should describe a single case or a small series of cases. They should present significant new insights on cases with a noteworthy course, striving to inform clinical cancer research and care. Case reports should draw attention to important clinical situations, unusual clinical phenomena, new treatment protocols, or new complications in a single patient or in a small number of patients. Manuscripts should be arranged according to the following sections: Title, Abstract, Introduction, Cases and Methods, Discussion and Conclusion. Case reports should contain up to 2,500 words, 3-6 figures and/or tables and up to 15 references. The journal follows the CARE guidelines (for CAse REports) to enhance accuracy, transparency, and usefulness of case reports. Authors are required to include the following information in case reports: Title - The diagnosis or intervention of primary focus followed by the words "case report". Key Words - 2 to 5 key words that identify diagnoses or interventions in this case report (including "case report"). Abstract - (structured or unstructured) Introduction - What is unique about this case and what does it add to the scientific literature? The patient's main concerns and important clinical findings. The primary diagnoses, interventions, and outcomes. Conclusion - What are one or more "take-away" lessons from this case report? Introduction - Briefly summarizes why this case is unique and may include medical literature references. Patient Information De-identified patient specific information. Primary concerns and symptoms of the patient. Medical, family, and psychosocial history including relevant genetic information. Relevant past interventions and their outcomes. Clinical Findings - Describe significant physical examination (PE) and important clinical findings. Timeline - Historical and current information from this episode of care organized as a timeline (figure or table). Diagnostic Assessment Diagnostic methods (PE, laboratory testing, imaging, surveys). Diagnostic challenges. Diagnosis (including other diagnoses considered). Prognostic characteristics when applicable. Therapeutic Intervention Types of therapeutic intervention (pharmacologic, surgical, preventive). Administration of therapeutic intervention (dosage, strength, duration). Changes in therapeutic interventions with explanations. Follow-up and Outcomes Clinician- and patient-assessed outcomes if available. Important follow-up diagnostic and other test results. Intervention adherence and tolerability. (How was this assessed?) Adverse and unanticipated events. Discussion Strengths and limitations in your approach to this case. Discussion of the relevant medical literature. The rationale for your conclusions. Conclusion The primary "take-away" lessons from this case report (without references) in a one paragraph conclusion. Patient Perspective - The patient should share their perspective on the treatment(s) they received when available and appropriate. Informed Consent - The patient should give informed consent.

Tumor Board Report: Tumor board reports are not case reports, but rather in-depth discussions of rare, difficult, or illuminating oncology conditions which should mirror the style of a clinical tumor board discussion. Manuscripts should be arranged according to the following sections: Clinical Presentation, Differential Diagnosis, Pathology, Options for Management (including possible roles for chemotherapy, radiation therapy, and surgery), Role of Targeted Therapy or Molecular Diagnostics, and Areas of Uncertainty. While Tumor Board Reports should incorporate exemplar cases, the emphasis should be on the authors' decision-making process regarding treatments and outcomes. Tumor board cases will have a maximum length of 2000 words, and are limited to 6 tables and/or figures and 10 references. A brief description of the case (limited to 150 words) is required.

Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address

All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided

Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)

Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Internet)
• A competing interests statement is provided, even if the authors have no competing interests to declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information on Ethics in publishing.

Studies in humans and animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Informed consent and patient details
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Declaration of competing interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors should complete the declaration of competing interest statement using this template and upload to the submission system at the Attach/Upload Files step. Note: Please do not convert the .docx template to another file type. Author signatures are not required. If there are no interests to declare, please choose the first option in the template. More information.
Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see ‘Multiple, redundant or concurrent publication’ for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Author contributions
For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. More details and an example

Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Copyright
Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (see more information on this). Permitted third party reuse of open access articles is determined by the author’s choice of user license.

Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Open access
Please visit our Open Access page for more information.

Elsevier Researcher Academy
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Please submit your article via https://www.editorialmanager.com/cpccr/default.aspx

PREPARATION

Peer review
This journal operates a double anonymized review process. All contributions are typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.
**Introduction**

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

This section contains all relevant case details, e.g. patient's history and characteristics, intervention, outcome, complications, and follow-up. Provide sufficient detail to allow the work to be reproduced by an independent researcher. Methods that are already published should be indicated by a reference: only relevant modifications should be described. State that the study and data accumulation were carried out with approval from the appropriate Institutional Review Board (IRB), Informed Consent for the research was obtained from the patients or subjects, and, for US authors, the study is in accordance with HIPAA regulations.

**Results**

Results should be clear and concise.

Explain the unique aspects of your case report, and define its significance, if any, to clinical practice. This section should explore the significance of the results of the work.

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion

**Appendices**

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

**Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

**Highlights**

Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

Abstracts should be **unstructured** and should succinctly summarize the main points of the case report. The abstract should be able to stand alone when retrieved by indexing services. Do not include abbreviations or references in the abstract.

**Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site. Authors can make use of Elsevier’s Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, ‘and’, ‘of’). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder’s requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

**Formats**

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format. Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

- EPS (or PDF): Vector drawings, embed all used fonts.
- TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
- TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
- TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

**Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

**Color artwork**

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites). Further information on the preparation of electronic artwork.

**Illustration services**

Elsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

**Figure captions**

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

**Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

**References**

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please
note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambhe W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal’s style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given. Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:
Reference to software:

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages.

Data visualization
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

Data linking
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.
In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

*Mendeley Data*
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

**AFTER ACCEPTANCE**

*Online proof correction*
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

*Offprints*
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier’s Author Services. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published. For further assistance, contact Researcher Support (support@elsevier.com).

© Copyright 2018 Elsevier | https://www.elsevier.com